Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

    “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said...

 May 17, 2024 | News

NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment

NeuShen Therapeutics , a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today a...

 May 10, 2024 | News

Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea

Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend BIO Korea (May 8-10, 2024) and formally open ...

 May 08, 2024 | News

Alnylam and Medison Expand Global Partnership to Accelerate Access to Innovative Therapies

  The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one glo...

 May 01, 2024 | News

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

 April 29, 2024 | News

Western Australia Boosts Biomedical Sector with Additional Funding for MTPConnect Training Programs

MTPConnect welcomes additional funding from the Western Australian Government to deliver critical industry training programs to boost the state’s bio...

 April 22, 2024 | News

Actinogen Medical Launches Phase 2b XanaMIA Trial for Alzheimer's, Marks First Patient Treatment

Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clin...

 April 16, 2024 | News

Cure Brain Cancer Foundation Launches Pioneering $575,000 Fellowship to Support Emerging Leaders in Brain Cancer Research

Cure Brain Cancer Foundation proudly unveiled the launch of its groundbreaking 5-Year Guardian Trust Early Career Fellowship, valued at $575,000. The...

 April 08, 2024 | News

Ractigen Therapeutics Launches Pioneering Phase I Clinical Trial for Bladder Cancer with First Patient Dosed in Collaboration with GenesisCare

Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone with the first patient dosed in its First-in-huma...

 April 04, 2024 | News

Resonance Health Joins Forces with Micron, Inc. for Strategic Entry into Japan's Healthcare Sector

Resonance Health Ltd, listed on the Australian Securities Exchange (ASX) under the ticker RHT, has officially announced its strategic move into the Japanes...

 March 28, 2024 | News

Alphamab Oncology Launches Groundbreaking Clinical Trial in Australia for Advanced Cancer Treatment

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed in Australia in the clinical study (JSKN033-101) of JSKN0...

 March 26, 2024 | News

Australia Grants AUD 17M to TB Alliance for Innovative Treatments

The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Allia...

 March 25, 2024 | News

Antengene Advances ATG-022 in Phase II CLINCH Study for Solid Tumors in China and Australia,

Antengene Corporation Limited, a prominent global biopharmaceutical entity focused on the development and commercialization of pion...

 March 21, 2024 | News

First Patient Treated in Phase 2 GvHD Trial

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, c...

 March 06, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in